Research Tracker›Biomarker Atlas›Long COVID›4-Aminobutanoate (GABA)

4-Aminobutanoate (GABA) in Long COVID

4-Aminobutanoate (GABA), also described as Inhibitory neurotransmitter precursor, is a metabolic marker reported as elevated in Long COVID (PASC, Post-Acute Sequelae of COVID-19) when patients are compared with recovered individuals without persistent symptoms. The cited literature links this alteration to neurotransmitter metabolism. This entry summarises Saito et al. 2024. Group-level associations like this do not translate into an individual diagnostic cut-off.

↑ ElevatedMetabolic

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryMetabolic
Also described asInhibitory neurotransmitter precursor
Compared againstR (recovered individuals without persistent symptoms)
Associated symptomsNeurotransmitter metabolism
Test typeBlood test (serum / plasma / whole blood)
SourceSaito et al. 2024 — doi:10.3389/fimmu.2024.1341843
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

Also sold as a nutrient or supplement

GABA (supplement). OTC neurotransmitter supplement (bioavailability debated). This tag means the analyte is also available orally; it is not a product endorsement and a low or high level does not by itself justify supplementation.

Related Metabolic markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is 4-Aminobutanoate (GABA) high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher 4-Aminobutanoate (GABA) in Long COVID than in recovered individuals without persistent symptoms. Source: Saito et al. 2024.

What symptoms is 4-Aminobutanoate (GABA) associated with in Long COVID?

The cited literature associates this marker with Neurotransmitter metabolism. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures 4-Aminobutanoate (GABA)?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal 4-Aminobutanoate (GABA) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. 4-Aminobutanoate (GABA) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). 4-Aminobutanoate (GABA) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/4-aminobutanoate-gaba.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.